Omeprazole/amoxicillin/rifabutin
Omeprazole/amoxicillin/rifabutin, sold under the brand name Talicia, is a fixed-dose combination medication used for the treatment of Helicobacter pylori infection.[1] It is taken by mouth.[1]
| Combination of | |
|---|---|
| Omeprazole | Proton-pump inhibitor |
| Amoxicillin | Penicillin-class antibacterial |
| Rifabutin | Rifamycin antibacterial |
| Clinical data | |
| Trade names | Talicia |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
It was approved for medical use in the United States in November 2019.[2]
References
- "Talicia- omeprazole magnesium, amoxicillin and rifabutin capsule, delayed release". DailyMed. Retrieved 4 October 2021.
- "Drug Approval Package: Talicia". U.S. Food and Drug Administration (FDA). 9 April 2020. Retrieved 4 October 2021.
External links
- "Omeprazole". Drug Information Portal. U.S. National Library of Medicine.
- "Amoxicillin". Drug Information Portal. U.S. National Library of Medicine.
- "Rifabutin". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03198507 for "ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator (ERADICATE Hp2)" at ClinicalTrials.gov
- Clinical trial number NCT01980095 for "ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 (ERADICATE Hp)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.